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Background: Tumour necrosis factor (TNF) and interferon gamma (IFN-γ), encoded by TNF-836 C/A (rs 1800630)
and IFN-γ -1616 C/T (rs2069705) genes, are key immunological mediators that are believed to both play protective
and pathological roles in malaria. The aim of this study was to investigate the relationship between TNF-836 C/A
and IFN-γ-1616 C/T polymorphism and susceptibility to severe malaria in pregnant women.
Methods: A prospective cohort (cross-sectional) study was conducted in pregnant women attending the out-patient
clinic in King Fahad Specialist Hospital in Jazan (KFSHJ), with a clinical diagnosis of malaria. A total of one hundred and
eighty six pregnant women were genotyped for single nucleotide polymorphism (SNP) for TNF and IFN-γ using
Taqman® MGB Probes. Serum cytokine concentrations were measured by sandwich ELISA method.
Results: A hospital case–control study of severe malaria in a Saudi population identified strong associations with
individual single-nucleotide polymorphisms in the TNF and IFN-γ genes, and defined TNF-836 C and IFN-γ-1616 T
genotypes and alleles which were statistically significantly associated with severe malaria infection. Furthermore,
TNF-836 CC and IFN-γ-1616 TT genotypes were associated with higher serum concentration of TNF and IFN-γ,
respectively, and with susceptibility to severe malaria.
Conclusions: This data provides a starting point for functional and genetic analysis of the TNF and IFN-γ genomic
region in malaria infection affecting Saudi populations.
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Malaria is one of the most important and prevalent in-
fectious diseases in the world. The World Health
Organization (WHO) estimated 219 million malaria
cases worldwide with 660,000 deaths due to Plasmo-
dium infection per year [1]. Women in endemic areas
become highly susceptible to malaria during their first
and second pregnancies, despite immunity acquired
after years of exposure [2]. These effects are most highly
associated with Plasmodium falciparum infections of
the placenta referred to as placental malaria (PM) [3].* Correspondence: gm_allam@yahoo.com
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unless otherwise stated.Malaria infection during pregnancy also increases the
risk of moderate/severe maternal anaemia, which is a
recognized risk factor leading to low birth-weight
(LBW) [4]. As there are over 85 million pregnant
women at risk of P. falciparum infection every year [5],
there is a need to better understand the mediators of
poor clinical outcome of pregnancy-associated malaria
(PAM) [6]. Both P. falciparum and P. vivax infections
can cause adverse pregnancy outcomes, including ma-
ternal anaemia and LBW due to preterm delivery and
foetal growth restriction, but the underlying mecha-
nisms could differ [7].
Host susceptibility to malaria is attributable to a number
of factors, which include the genetic background of both
host and pathogen. Indeed host genetic factors are involved
in the regulation of the individual’s immunological compe-
tence. Several chromosomal regions containing genesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cated in the control of P. falciparum infection levels [8–10].
Substantial increase in tumour necrosis factor (TNF)
[11–14], and interferon gamma (IFN-γ) [11, 15], have
been found in placental blood or tissue in response to
malaria infection. These cytokines are known to aid in the
elimination of parasites from the placenta by enhancing
phagocytic activity of macrophages, generating reactive
oxygen intermediates and L-arginine-derived nitric oxide,
and stimulating the proliferation of T cells. Thus, Th1-
type responses are of parasitological importance. However,
overproduction can jeopardize the pregnancy, as Th1 re-
sponse is associated with maternal anaemia, spontaneous
abortions, and premature deliveries [16].
Host genetic factors have been shown to influence
malaria infection intensity and clinical malaria. Several
candidate genes have been associated with resistance
against severe malaria, whereas linkage or association
analyses mapped several loci controlling mild malaria
and/or parasitaemia [17].
The first aim of this study was to examine TNF and
IFN-γ cytokine concentrations in pregnant women with a
clinical diagnosis of malaria. Those women were attending
the outpatient clinics at King Fahad Specialist Hospital in
Jazan (KFSHJ), Saudi Arabia. The second aim of this study
was to investigate whether TNF −836 C/A (rs 1800630)
and IFN-γ-1616 C/T (rs2069705) genotypes and alleles
frequency, are associated with susceptibility to either
uncompleted or severe malaria infection among Saudi
women living in the southern part of Saudi Arabia. The
third aim of the study was to examine the association be-
tween single nucleotide polymorphism (SNP) in promoter
regions of TNF and IFN-γ and cytokine levels.
Methods
Study area
This study was conducted in Jazan city in the southern
Kingdom of Saudi Arabia (KSA), during the dry season,
March 2012 to August 2013. The study area was previ-
ously described in detail by Nasr et al. [18].
Study design and patient enrolment
A prospective cohort (cross-sectional) study was con-
ducted in pregnant women attending the out-patient
clinic in King Fahad Specialist Hospital in Jazan (KFSHJ),
with a clinical diagnosis of malaria. Patients with symp-
tomatic malaria are those with one or more of the classical
symptoms of malaria infection as described by the WHO
[19]. Patients were recruited after written informed con-
sent was gained from them. Blood samples were taken for
confirmation of malaria. Once patients were found to be
positive for malaria, treatment was offered. Patients
with symptomatic malaria (Uncomplicated Malaria,
UM) in their first trimester of pregnancy receivedquinine (20 mg/kg loading dose) plus clindamycin for
seven days. Patients in their second and third trimesters re-
ceived ACT. Standard ACT was artemisinin (4 mg/kg/day)
given on days 0–2 and a single dose of sulphadoxine-
pyrimethamine (25 mg/kg) given on day 0 [20–22]. Patients
with severe malaria (SM) received artesunate plus quinine
(10 mg/kg/8 hours). All patients were reviewed by the
study gynecologist to confirm that there were no other
co-infections apart from malaria. No one from the study
groups was found to be HIV positive. All patients with
other infectious diseases were excluded from the study.
The study is part of a longitudinal research and is described
previously by Nasr et al. [18]. The study was reviewed and
approved by the Ethics Review Committee in the College of
Medicine at Taif University.
Sample collection
Before pharmacological treatment was started, 3 ml of
venous blood sample was collected into EDTA Vacutai-
ner® tubes (Becton Dickinson, Meylan, France) for para-
site measurements. This was put into thick and thin
blood smears obtained at the time of collection, which
were then stained with Giemsa. The blood samples were
separated and plasma samples were stored at −80°C
until used for the cytokines analysis.
Microscopic observation
Thick and thin films were made for microscopic examin-
ation using standard Giemsa staining. Parasite densities
were determined by counting the number of parasites per
1,000 erythrocytes in thin film.
Serum and DNA extraction
Genomic DNA was purified from blood using a com-
mercial DNA purification kit QIAmp® DNA blood mini
kit (Qiagen, Hilden, Germany) [23].
Parasite genotype
Five μl of DNA samples were used to detect the P. fal-
ciparum malaria parasite using a polymerase chain reac-
tion (PCR), targeting for msp2 (FC27) clone as described
in details below. Nested PCR was performed to deter-
mine the numbers of msp2 (FC27) clone. Amplifications
were done in 10 μl reaction mixture containing DNA
template, iProof™ High-Fidelity Master Mix (BIO-RAD
Laboratories, Hercules, CA) and 500 nM of primer pairs.
The methodology and sequences of used primers have
been presented in detail elsewhere in [24] and [25], re-
spectively. For the negative controls, blood samples were
collected from Swedish individuals who were never ex-
posed to P. falciparum malaria parasites. For the positive
controls, blood samples were collected from Sudanese
individuals who have been exposed to P. falciparum
malaria parasites in the past.
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Single nucleotide polymorphism (SNP) for TNF-863 C/
A (rs1800630) and IFN-γ -1616 C/T (rs2069705) were
analysed with Taqman® MGB Probes from Applied Bio-
systems according to the manufacturers protocol as pre-
viously mentioned in [26, 27].
Cytokine concentrations
Serum cytokine concentrations were measured by the
sandwich ELISA method [11, 28]. The following Abs
were used: IFN-γ, mAb 1-D1K and mAb 7-b6-1-biotin
(MABTECH, Nacka, Sweden); TNF, mAb, and poly-
clonal Ab (Genzyme, Cambridge, MA). Detection limits
for cytokines were: IFN-γ and TNF 1.0 pg/ml [11].
Statistical analysis
The distribution of cytokine [TNF and IFN-γ] genotype,
allele’s frequencies and [TNF and IFN-γ] concentra-
tion were analysed using SPSS version 16.0 (SPSS, Inc,
Chicago, IL, USA). Logistic regression analyses were per-
formed to assess associations of genotype (dependent
variable) and risk of malaria severity. Associations were
quantified using odds ratios [OR] with 95% confidence
intervals (CI), which when they do not cross 1.00, it is
defined as statistically significant. The [TNF and IFN-γ]
heterozygote group were used as a reference in the ana-
lyses. Using the same software to perform an overall
comparison of allele frequency using a 2 × 2 chi-square
test. Differences in cytokine [TNF and IFN-γ] concentra-
tions between different study groups were analysed using
Kruskal-Wallis test and P- value will be corrected for
ties. Logistic regression analyses were performed to as-
sess the association between the cytokine [TNF and




A total of one hundred and eighty six pregnant women,
were consecutively enrolled in the study and were classi-
fied into three groups according to malaria outcome.
Group I: Malaria free control (MFC), were malaria para-
site negative and had no clinical symptoms of malaria in-
fection [n = 60 (32.3%); median age of 22 with a range of
(18–26) years] (Table 1). Group II: Uncomplicated malaria
patients (UM) were malaria parasites positive and had one
or more of the classical symptoms of malaria infection
[n = 62 (33.3%); median age of 22 with a range of (18–26)
years]. The median of parasite density was 1,200 with a
range of 250–2,000 parasite/μl. This is a relatively low
parasite density according to the WHO criteria [19]
(Table 1). Group III: Severe malaria patients (SM) [n = 64
(34.4%); median age of 20 with a range of (18–22) years]
were malaria parasites positive and fulfilled one or moreof the WHO criteria for severe (complicated) P. falcip-
arum [median of parasite density was 2,400 with a range
of 2,000-2,800 parasite/μl) (Table 1). The serum concen-
tration of TNF and IFN-γ cytokines were statistically sig-
nificantly higher in SM patients compared to other groups
(Overall P value <0.001 for both cytokines) (Table 1).
Overall, there was statistical difference in the median and
range of mother's age in malaria outcome P value <0.001
(Table 1).
Overall, there was statistical difference in the median
of the parasite density which was significantly higher in
SM compared to UM patients (P value <0.001, Table 1).
All women attending the outpatient clinic at the time of
enrolment were analysed initially by microscopy of
blood film, and subsequent confirmation by PCR as
mentioned in parasite genotype section.
The characteristics of the pregnant women are shown
in Table 1. The prevalence of malaria parasites density
during the pregnancy duration were statistically signifi-
cantly higher in pregnant women during the first and
second trimesters when compared with the pregnant
women in their third trimester; overall P value = 0.008
(Table 1). However, no statistical difference was seen
between the first and second trimester regarding the
prevalence of parasites density, which were observed
between SM (P value = 0.383; Table 1).
Description of gravid, ABO blood group and malaria
complications among the study groups
One of the findings is that younger women (20 years
old) were at higher risk of severe malaria than older
women; overall P value = 0.001 (Table 1). The prevalence
of malaria infection in the pregnant women with primi-
gravidae was higher than those with multigravidae
(P value <0.001) (Table 2). Pregnant women carrying
O blood group were associated with severe malaria
compared with other ABO blood groups (overall
P value <0001, Table 2).
Table 2 shows that 76.6% of SM patients had severe
normocytic anaemia (haemoglobin <7 g/dl, and haem-
atocrit <20%) due to the malaria infection which was
statistically significantly higher compared to those with
cerebral malaria (unrousable coma), convulsions (more
than two per 24 hours), (12.5%) and hypoglycaemia (blood
glucose <2.2 mmol/l) (10.9%); overall P value <0.001
(Table 2). Among 62 pregnant women diagnosed with
UM, 43 (69.6%) in the first trimester were treated by quin-
ine compared with 30.4% pregnant women in their second
and third trimester of pregnancy who were treated with
artemisinin-based combination therapy (ACT). All 64
patients with severe malaria were treated with artesunate
plus quinine (overall P value <0.001, Table 2). There were
no deaths within the cases of UM or SM malaria noted
during the study.
Table 1 Description the median and range of parasitological, cytokine (TNF, IFN-γ), age and Hb among the
study group
Diagnosis Trimester Parasite TNF IFN-γ pg/ml Age Hb
gm/dlpg/ml
MFC n = 60 First trimester n = 13 Median 1.76 2.83 21 14
Range 1.44- 2.17 2.01- 2.85 18-26 10- 16
Second trimester n = 13 Median 1.87 2.83 22 13
Range 1.36- 2.08 2.73- 3.26 18-26 10- 16
Third trimester n = 34 Median 1.81 2.84 23 14
Range 1.38- 2.21 2.01- 2.98 18- 26 10- 16
P valueΨ within the subgroups 0.370 0.283 0.129 0.451
UM n = 62 First trimester n = 43 Median 1300 5.65 4.37 23 13
Range 250- 2000 5.14- 6.10 2.64- 5.38 18-26 12-14
Second trimester n = 12 Median 1150 5.60 4.72 22 13
Range 510- 2000 5.30- 6.03 2.70- 5.37 18-26 12- 14
Third trimester n = 7 Median 600 5.66 4.63 21 13
Range 320- 650 5.58- 5.78 2.63- 5.36 18-26 12- 14
P valueΨ within the subgroups 0.008 0.797 0.478 0.944 0.573
SM n = 64 First trimester n = 46 Median 2400 7.95 7.51 20 10
Range 2000- 2800 5.72- 43.64 5.40- 19.50 18-22 8- 13
Second trimester n = 14 Median 2400 8.35 7.57 20 9.5
Range 2000- 2800 6.22- 21.28 5.52- 16.22 18-22 8- 12
Third trimester n = 4 Median 1250 7.16 6.65 20 10
Range 1000- 2000 6.39- 8.66 5.60- 7.66 19- 22 8.9- 12
P valueΨ within the subgroups 0.383 0.635 0.565 0.771 0.754
Overall P value* between the groups <0.001 <0.001 <0.001 0.001 0.001
ΨP value was calculated between the groups using one way ANOVA test.
*P value was calculated between the groups using non-parametric test (Kruskal-Wallis).
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The TNF-863 C/A and IFN-γ-1616 C/T genotype and allele
frequencies amongst the control group and the patients of
SM and UM were found to be in Hardy-Weinberg equilib-
rium (for TNF-863 C/A genotype and allele; P value = 0.61
and 0.33, respectively) and for (IFN-γ-1616 C/T genotype
and allele; P value = 0.57 and 0.21, respectively) (Table 3).
The overall TNF-863 C/A genotypic and allelic frequencies
differed statistically significantly between SM and UM pa-
tients compared to the MFC group [Overall genotypic fre-
quency; Odds Ratio [OR] = 6.75, 95% Confidence Interval
[CI] = (1.35- 33.77), P value = 0.020] and [Overall allelic fre-
quency; OR = 2.15, 95% CI = (1.54- 4.69), P value = 0.001]
(Table 3). The overall IFN-γ -1616 C/T genotypic and allelic
frequencies differed statistically significantly between SM
and UM patients compared to the MFC group [Overall
genotypic frequency; OR = 8.50, 95% CI = (2.19- 12.95),
P value = 0.002] and [Overall allelic frequency; OR = 1.76,
95% CI = (0.12- 3.95), P value = 0.014] (Table 3).
Logistic regression analysis revealed that the TNF −863
CC genotype is significantly higher amongst SM groupcompared to the UM group [OR = 4.64, 95% CI = (1.85-
11.64), P value <0.001] (Table 4). The frequency of the
C-allele was statistically significantly dominant in SM
patients compared to the UM patients [69% for C-allele in
UM versus 91% for C-allele in SM; OR 0.24, 95% CI (0.07-
0.68) and P value = 0.003] (Tables 3 and 4).
Logistic regression analysis showed that the IFN-γ-
1616 TT genotype is significantly higher amongst SM
group compared to the UM group [OR = 5.53, 95% CI =
(2.30- 13.27), P value <0.001] (Table 5). The frequency
of the T-allele was statistically significantly dominant in
SM patients compared to the UM patients [60% for T-
allele in UM versus 88% for T-allele; OR 0.24, 95% CI
(0.07- 0.68) and P value = 0.003] (Tables 3 and 4).
Association of TNF-863 C/A, IFN-γ-1616 C/T genes
polymorphism and serum TNF, IFN-γ concentration
The relationship between the TNF-863 C/A polymorph-
ism and serum TNF concentration was analysed regard-
less of the differences in the study groups. As shown
in Table 6, the homozygous TNF-863 CC genotype is
Table 2 Description of gravid, ABO blood group and malaria complications among the study groups
Dependant variables MFC UM SM P value
n = 60 (32.3%) n = 62 (33.3%) n = 64 (34.4%)
Gravidae <0.001
Primigravidae 4 (6.7%) 54 (87.1%) 56 (87.5%)
n = 114 (61.3%)
Multigravidae 56 (93.3%) 8 (12.9%) 8 (12.5%)
n = 72 (38.7%)
ABO <0.001
O n = 124 (66.7%) 44 (73.3%) 37 (59.7%) 43 (67.2%)
A n = 20 (10.8%) 8 (13.3%) 4 (6.5%) 8 (12.5%)
B n = 30 (16.1%) 4 (6.7%) 18 (29%) 8 (12.5%)
AB n = 12 (6.5%) 4 (6.7%) 3 (4.8%) 5 (7.8%)
Malaria complications <0.001
No complications 60 (100%) 62 (100%) 0 (0%)
Anaemia 0 (0%) 0 (0%) 49 (76.6%)
Cerebral malaria 0 (0%) 0 (0%) 8 (12.5%)
Hypoglycaemia 0 (0%) 0 (0%) 7 (10.9%)
Treatment <0.001
No treatment 60 (100%) 0 (0%) 0 (0%)
Quinine 0 (0%) 43 (69.4%) 0 (0%)
ACT* 0 (0%) 19 (30.6%) 0 (0%)
Artesunate plus quinine 0 (0%) 0 (0%) 64 (100%)
*Artemisinin-based combination therapy (ACT).
Table 3 Distribution and logistic regression analysis of the cytokine (TNF, IFN-γ) genotypes and allele frequency in
relation to severe (SM) compared with uncomplicated malaria (UM) and malaria free control (MFC)
Dependent
variable
MFC UM SM Hardy-Weinberg
equilibrium testn = 60(%) n = 62(%) n = 64(%)
TNF −863 C/A*
CC 6 (6.5%) 32 (34.8%) 54 (58.7%) 0.61
CA 27 (47.4%) 22 (38.6%) 8 (14.0%)
AA 27 (73%) 8 (21.6%) 2 (5.4%)
Alleles frequency‡
C 0.32 0.69 0.91 0.33
A 0.62 0.31 0.09
IFN-γ -1616 T/C¥
TT 2 (2.6%) 24 (31.2%) 51 (66.2%) 0.57
CT 35 (49.3%) 26 (36.6%) 10 (14.1%)
CC 23 (60.5%) 12 (31.6%) 3 (7.9%)
Alleles frequency£
T 0.33 0.60 0.88 0.21
C 0.67 0.40 0.12
*Overall genotypic frequency; Odds Ratio [OR] = 6.75; 95% Confidence Interval [CI] = (1.35- 33.77), P value = 0.020.
‡Overall allelic frequency; OR = 2.15; 95% CI = (1.54- 4.69), P value = 0.001.
¥Overall genotypic frequency; OR = 8.50; 95% CI = (2.19- 12.95), P value = 0.002.
£Overall allelic frequency; OR = 1.76; 95% CI = (0.12- 3.95), P value = 0.014.
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Table 4 Logistic regression analysis of TNF-863 C/A
genotype and allele frequency among SM compared with
UM patients
TNF −863 C/A OR‡ (95% CI) P value
Genotypes
CC 4.64 (1.85-11.64) <0.001
CA 1.00
AA 0.69 (0.12- 3.94) 0.67
Alleles frequency
C 0.24 (0.07- 0.68) 0.003
A
‡OR represent odds ratios while CI represents confidence intervals.
Uncomplicated malaria patients (UM) were assigned 0 while severe malaria
(SM) patients were assigned 1 in the logistic regression analysis. OR above 1
represented value associated to SM patients while less than 1 value
represented to UM patients.
Table 6 Logistic regression analysis of TNF −863 C/A and
IFN-γ -1616 T/C genotypes in association to TNF and
IFN-γ concentration (pg/mL) respectively in the combined
study groups
Genotypes OR‡ (95% CI) P value
TNF −863
CC 4.04 (2.01- 8.13) <0.001
CA 1.00
AA 0.31 (0.11- 0.86) 0.024
IFN-γ -1616
TT 8.49 (4.03- 17.91) <0.001
TC 1.00
CC 0.81 (0.33- 1.92) 0.002
‡OR represent odds ratios while CI represents confidence intervals. Lower
levels of TNF (mean ± SD; 2.99 ± 1.24) and IFN-γ (4.01 ± 1.94) concentration
were assigned 0 while severe malaria (SM) patients were assigned 1 in the
logistic regression analysis. OR above 1 represented value associated to SM
patients while less than 1 value represented to UM patients.
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the whole study groups compared to the heterozygous
TNF-863 CA genotype [OR = 4.04, 95% CI = (2.01- 8.13),
P value <0.001] (Table 6). In contrast, the homozygous
TNF-863 AA genotype is significantly associated with lower
levels of TNF in the combined study population compared
to the heterozygous TNF-863 CA genotype [OR = 0.31,
95% CI = (0.11- 0.86), P value = 0.024] (Table 6).
The association between the IFN-γ -1616 C/T poly-
morphism and the concentration of IFN-γ was analysed
regardless of the difference in the study groups. The
homozygous IFN-γ -1616 TT genotype is significantly
associated with higher concentration of IFN-γ compared
to the heterozygous IFN-γ -1616 TC genotype [OR =
8.49, 95% CI = (4.03- 17.90), P value <0.001] (Table 6).
However, the homozygous IFN-γ -1616 CC had no in-
fluence in the concentration of serum IFN-γ amongst
the study population compared with the heterozygous
IFN-γ -1616 TC genotype [OR = 0.81, 95% CI = (0.33-
1.92), P value = 0.610] (Table 6).Table 5 Logistic regression analysis of IFN-γ -1616 T/C
genotype and allele frequency among SM compared with
UM patients
IFN-γ -1616 T/C Genotypes OR‡ (95% CI) P value
TT 5.53 (2.30- 13.27) <0.001
TC 1.00
CC 0.65 (0.15- 2.80) 0.56
Alleles frequency
T 0.28 (0.10- 0.76) 0.008
C
‡OR represent odds ratios while CI represents confidence intervals.
Uncomplicated malaria patients (UM) were assigned 0 while severe malaria
(SM) patients were assigned 1 in the logistic regression analysis. OR above 1
represented value associated to SM patients while less than 1 value
represented to UM patients.Discussion
The present study suggests that the prevalence malaria
infection is higher in pregnant women during the first
trimester compared to second and third trimesters. This
finding was reported previously in the same study area
[18]. The data presented here suggests that the youngest
mothers, who are less than 21 years old, are more sus-
ceptible to severe malaria compared to other age groups.
A previous study in Mali suggested that young age is an
important risk factor for malaria infection in pregnant
women [29]. Thus, control measures against malaria in-
fection should target younger rural women in their first
trimester of pregnancy [29].
The data presented here suggests that the prevalence
of malaria parasite’s density during the pregnancy dur-
ation were statistically significantly higher in pregnant
women during the first and second trimesters. A previ-
ous study suggested that the peaks of peripheral parasit-
aemia is around 8 to 15 weeks of gestation [30]. In the
present study, the prevalence of malaria infection in
the primigravidae was higher than those who were
multigravidae. This corresponds well with the finding
that IgG responses [variant surface antigens specific to
pregnancy associated malaria (VSAPAM-specific)] appear
around weeks 18 to 20 in primigravidae and somewhat
earlier in multigravidae [31, 32].
The present study found that pregnant women carry-
ing the O blood group were associated with severe mal-
aria compared with those non-O blood group carriers.
Several studies from Gabon, Gambia, Malawi and Sudan
[33–36] suggested that there is a tendency towards a
protective effect of the blood group O against placental
malaria infection regardless of parity; however this was
not statistically significant. The higher risk of placental
parasitaemia in primiparae with blood group O that was
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The significant association of blood group O with placen-
tal malaria in primiparae and the reduced risk of placental
infection in multiparae that was found in the recently
published paper from Gambia [34] and Malawi [36] was
not confirmed by a study conducted in Sudan [33].
One of the main findings of the present study is that
severe anaemia is the predominant presenting manifest-
ation of severe P. falciparum malaria observed during
pregnancy in the Southern part of Saudi Arabia. With
the exception of low temperatures, other clinical and
biochemical criteria were not different amongst women
with different criteria of severe P. falciparum malaria.
Interestingly however, severe anaemia had been observed
as the presenting manifestation of severe P. falciparum
malaria in pregnant women in central and eastern Sudan
[37, 38].
Pro-inflammatory cytokines, especially TNF, IFN-γ
and lymphotoxin (LT), have been associated with severe
malaria disease and are still crucial for the initial control
of parasitaemia in human. The mechanisms are not yet
well understood, but secretion of IFN-γ by NK cells, and
γδT-cells may have cytotoxic effects on parasite growth
as well as activate monocytes and macrophages and en-
hance non-opsonic phagocytosis of iRBCs. The present
study shows that higher levels of TNF and IFN-γ were
increasing significantly in UM and SM patients com-
pared to MFC. This observation in SM suggests an im-
balanced production of inflammatory cytokines that
could contribute to severe malarial anaemia and higher
parasite density associated with SM. TNF is an import-
ant cytokine in malaria within pregnancy and its levels
must be carefully regulated. Low levels are necessary for
enhancing phagocytic activity and controlling parasite
densities [39, 40], but high levels of TNF can trigger in-
hibition of endocrine function and initiate extracellular
matrix degradation, resulting in poor pregnancy out-
comes [41, 42].
High concentrations of TNF are related to the patho-
genesis of symptoms associated with malaria infection,
such as fever and severe forms of infection, such as cere-
bral malaria [43, 44]. The biological activity of TNF can
be modulated, in part, by its soluble receptors, sTNFR1
and sTNFR2 [45] that are shed from the surface of a
number of different cell types by proteolysis. The soluble
form of the receptors can stabilize TNF when the cyto-
kine is present in low concentrations in plasma or
neutralize TNF by competing for occupation of the re-
ceptors on the cell surface when the cytokine is in excess
in the local environment [46]. Another suggestion is that
the malaria infection also involves elevated production
of IgE antibodies [47]. However, IgE-containing immune
complexes are pathogenic rather than protective by cross-
linking IgE receptors (CD23) on monocytes, leading tolocal overproduction of TNF, a major pathogenic factor in
this disease [47]. T cells are essential for both acquisition
and regulation of malaria immunity [47].
The study observed that the IFN-γ cytokine was statis-
tically significantly higher in SM patients compared to
UM and MFC. Available studies in both humans and
mice have demonstrated the importance of an early IFN-
γ response as a crucial determinant in the outcome of
the infection and the well-being of the patient [48–50].
However, IFN-γ has also been associated with the pres-
ence of potent anti-parasitic activity, and persistent high
levels of the cytokine can lead to a rapid improvement
in fever and reduction in parasitaemia [51, 52]. The
present results suggest that the increased levels of IFN-γ
seen in infected patients may play a critical role in
susceptibility to severe malaria in these groups. In par-
ticular, the production of endogenous pyrogens such
as TNF, IL-1β and IL-6 following IFN-γ stimulation of
monocytes/macrophages may be responsible for fever
induction [53] and sustained IL-1β production may be
associated with anaemia [54]. The potential roles of
pro-inflammatory cytokines in pathology in the setting
of maternal malaria are reviewed elsewhere [6].
Population differences in susceptibility or resistance to
malaria according to TNF SNPs may be a result of di-
verse evolutionary pressure between ethnicity, as well as
different parasite strains and incidence of severe forms
of disease. A recent study in sympatric ethnic groups liv-
ing in Mali suggested that a few TNF diplotypes showed
an interesting potential influence on severity rather than
susceptibility to infection [26]. Previous studies sug-
gested that higher levels of TNF cytokine have been cor-
related with malaria severity and death [55, 56], and
several SNPs in the promoter region of the TNF gene
have been associated with different outcomes and sever-
ity of a malaria infection [57–60]. The only recent study
that analysed the association between TNF-863 C/A
polymorphism and susceptibility to malaria infection,
suggested that TNF-863 CC genotype was statistically
significantly associated with malaria infection in sympat-
ric ethnic groups living in Mali [26]. The data presented
in this report indicates that the homozygous TNF-863
CC genotype was significantly associated with higher
levels of TNF cytokine. A previous study in Sweden sug-
gested that individuals carrying TNF-863 CC genotype
have a significantly higher serum TNF level. However,
donors carrying the TNF-863 AA have a significantly
lower serum TNF-cytokine level [61].
With regards to the IFN-γ-1616 TT genotype, it is
statistically significantly associated with SM patients.
Additionally, the IFN-γ-1616 TT genotype is associated
with increased serum concentration of IFN-γ cytokine.
A previous study suggested that the IFN-γ promoter
polymorphisms that increase the gene expression may
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vide evidence that the IFN-γ-1616 TT genotype is asso-
ciated with higher level of IFN-γ among SM patients
compared to UM patients and MFC group respectively.
Conclusions
Taken together, the allele frequency of TNF-836 C and
IFN-γ-1616 T genes were statistically significantly higher
in those with severe malaria infection compared to un-
complicated malaria patients. Furthermore, TNF-836 CC
and IFN-γ-1616 TT genotypes were associated with higher
serum concentration of TNF and IFN-γ, respectively, and
with susceptibility to severe malaria. This data provides a
starting point for functional and genetic analysis of the
TNF and IFN-γ genomic region in malaria infection affect-
ing Saudi populations.
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